A Polymeric Dexamethasone Prodrug Attenuates Focal Segmental Glomerulosclerosis (FSGS) in an Adriamycin-induced Mouse Model with Minimal Glucocorticoid Side Effects

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Smart Materials in Medicine

• Publication date

  2025-02-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/j.smaim.2025.02.003
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Reversal of Doxorubicin-Induced Bone Loss and Mineralization by Supplementation of Resveratrol and MitoTEMPO in the Early Development of Sparus aurata

  2022cited by this paper
• Doxorubicin Induces Bone Loss by Increasing Autophagy through a Mitochondrial ROS/TRPML1/TFEB Axis in Osteoclasts

  2022cited by this paper
• Interventions for focal segmental glomerulosclerosis in adults.

  2022cited by this paper
• Efficacy and Safety of ACE Inhibitor and Angiotensin Receptor Blocker Therapies in Primary Focal Segmental Glomerulosclerosis Treatment: A Systematic Review and Meta-Analysis

  2022cited by this paper
• Dexamethasone Administration in Mice Leads to Less Body Weight Gain over Time, Lower Serum Glucose, and Higher Insulin Levels Independently of NRF2

  2021cited by this paper
• Dual-Regulated Functionalized Liposome-Nanoparticle Hybrids Loaded with Dexamethasone/TGFβ1-siRNA for Targeted Therapy of Glomerulonephritis.

  2021cited by this paper
• Understanding and Managing Corticosteroid-Induced Osteoporosis

  2021cited by this paper
• Therapeutic trials in adult FSGS: lessons learned and the road forward

  2021cited by this paper
• Nanomedicine for acute respiratory distress syndrome: The latest application, targeting strategy, and rational design

  2021cited by this paper
• Autoimmunity in Focal Segmental Glomerulosclerosis: A Long-Standing Yet Elusive Association

  2020cited by this paper
• Emerging drugs for treatment of focal segmental glomerulosclerosis

  2020cited by this paper
• Anti-CD20-mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives.

  2020cited by this paper
• Head-to-head comparative pharmacokinetic and biodistribution (PK/BD) study of two dexamethasone Prodrug Nanomedicines on lupus-prone NZB/WF1 mice.

  2020cited by this paper
• Advanced nanomedicines for the treatment of inflammatory diseases

  2020cited by this paper
• Dexamethasone Prodrug Nanomedicine (ZSJ-0228) Treatment Significantly Reduces Lupus Nephritis in Mice without Measurable Side Effects - A 5-Month Study.

  2020cited by this paper
• Plasma albumin and calcium concentrations, and long-term mortality in primary health care patients in Sweden

  2020cited by this paper
• Focal Segmental Glomerulosclerosis: State-of-the-Art and Clinical Perspective

  2020cited by this paper
• Open-Label Clinical Trials of Oral Pulse Dexamethasone for Adults with Idiopathic Nephrotic Syndrome

  2019cited by this paper
• Micelle-Forming Dexamethasone Prodrug Attenuates Nephritis in Lupus-Prone Mice without Apparent Glucocorticoid Side Effects

  2018cited by this paper
• Recent advances of animal model of focal segmental glomerulosclerosis

  2018cited by this paper
• Transport and interactions of nanoparticles in the kidneys

  2018cited by this paper
• Polymer-drug conjugates in inflammation treatment.

  2018cited by this paper
• Patient perceptions of glucocorticoid side effects: a cross-sectional survey of users in an online health community

  2017cited by this paper
• Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update

  2017cited by this paper
• Immune regulation by glucocorticoids

  2017cited by this paper
• Distribution of Biopsy-Proven Presumed Primary Glomerulonephropathies in 2000-2011 Among a Racially and Ethnically Diverse US Population.

  2016cited by this paper
• FSGS: Diagnosis and Diagnostic Work-Up

  2016cited by this paper
• Podocyte-Specific Deletion of Yes-Associated Protein Causes FSGS and Progressive Renal Failure.

  2016cited by this paper
• Bone mechanical properties and changes with osteoporosis.

  2016cited by this paper
• Effects of Tumor Necrosis Factor-α on Podocyte Expression of Monocyte Chemoattractant Protein-1 and in Diabetic Nephropathy

  2015cited by this paper
• Nanomedicines for inflammatory arthritis: head-to-head comparison of glucocorticoid-containing polymers, micelles, and liposomes.

  2014cited by this paper
• Nephrotic syndrome: components, connections, and angiopoietin-like 4-related therapeutics.

  2014cited by this paper
• Pathophysiology and treatment of focal segmental glomerulosclerosis: the role of animal models

  2013cited by this paper
• Association of histologic variants in FSGS clinical trial with presenting features and outcomes.

  2013cited by this paper
• A Dexamethasone Prodrug Reduces the Renal Macrophage Response and Provides Enhanced Resolution of Established Murine Lupus Nephritis

  2013cited by this paper
• Mechanisms of Action of Topical Corticosteroids in Psoriasis

  2012cited by this paper
• Alanine Aminotransferase: A Clinical and Regulatory Tool for Detecting Liver Injury–Past, Present, and Future

  2012cited by this paper
• Development of macromolecular prodrug for rheumatoid arthritis.

  2012cited by this paper
• Immunosuppressive treatment of focal segmental glomerulosclerosis: lessons from a randomized controlled trial.

  2011cited by this paper
• Clinical trial of focal segmental glomerulosclerosis in children and young adults.

  2011cited by this paper
• Rituximab Targets Podocytes in Recurrent Focal Segmental Glomerulosclerosis

  2011cited by this paper
• Corticosteroids Increase Protein Breakdown and Loss in Newly Diagnosed Pediatric Crohn Disease

  2011cited by this paper
• Glucocorticoids decrease body weight and food intake and inhibit appetite regulatory peptide expression in the hypothalamus of rats.

  2011cited by this paper
• Molecular Mechanism of Cyclodextrin Mediated Cholesterol Extraction

  2011cited by this paper
• Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans.

  2009cited by this paper
• Advances in the biology and genetics of the podocytopathies: implications for diagnosis and therapy.

  2009cited by this paper
• Evaluation and management of steroid-unresponsive nephrotic syndrome

  2008cited by this paper
• Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization.

  2008cited by this paper
• The Early Effects of Short-Term Dexamethasone Administration on Hepatic and Serum Alanine Aminotransferase in the Rat

  2008cited by this paper
• Intramuscular absorption and biodistribution of dexamethasone from non-aqueous emulsions in the rat.

  2007cited by this paper
• Antiinflammatory action of glucocorticoids--new mechanisms for old drugs.

  2005cited by this paper
• The role of glucocorticoid action in the pathophysiology of the Metabolic Syndrome

  2005cited by this paper
• Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States.

  2004cited by this paper
• Evaluation of abnormal liver function tests

  2003cited by this paper
• Bone histomorphometry in untreated and treated glucocorticoid-induced osteoporosis.

  2002cited by this paper
• Molecular and cellular endocrinology

  2000cited by this paper
• Effect of single chemotherapeutic agents on the growing skeleton of the rat.

  2000cited by this paper
• Long‐Term Corticosteroid Therapy Induces Mild Changes in Trabecular Bone Texture

  2000cited by this paper
• A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group.

  1999cited by this paper
• Glucocorticoid-induced granulocytosis: contribution of marrow release and demargination of intravascular granulocytes.

  1998cited by this paper
• The science and therapy of glucocorticoid-induced bone loss.

  1998cited by this paper
• [Tumor necrosis factor (TNF) and interleukin-6 (IL-6) in patients with glomerulonephritis].

  1996cited by this paper
• Body composition of mice of different body condition score and sex.

  1996cited by this paper
• Mechanism of glucocorticoid-induced increase in pancreatic amylase gene transcription.

  1987cited by this paper
• Hypercalcemia. A complication of advanced chronic liver disease.

  1987cited by this paper
• Glucocorticoids increase amylase mRNA levels, secretory organelles, and secretion in pancreatic acinar AR42J cells

  1985cited by this paper
• The Role of the Kidney in the Elimination of Pancreatic Lipase and Amylase from Blood

  1985cited by this paper
• Effects of chemotherapeutic agents on bone. I. Short-term methotrexate and doxorubicin (adriamycin) treatment in a rat model.

  1984cited by this paper
• The effect of dexamethasone on renal potassium excretion and acute potassium tolerance.

  1983cited by this paper
• Effect of dexamethasone on electrolyte transport in the large intestine of the rat.

  1978cited by this paper
• Amylase isoenzyme clearances in normal subjects and in patients with acute pancreatitis.

  1976cited by this paper

• No citing papers are available for this paper.